Exploiting RNA to improve healthcare

Biogazelle is a Contract Research Organization specializing in high-value applications to support pharmaceutical research, clinical trials and diagnostic test development. We help our clients accelerate the development of therapeutics, including small molecules, RNA targeted drugs, and adoptive cell therapies.

Biomarker Discovery and Development

At Biogazelle, we apply a suite of genomic and transcriptomic technologies, to identify, validate and develop RNA and DNA biomarkers in the context of drug discovery and development. Through the combination of RNA sequencing and advanced model building, our biomarker development platform aims at establishing a complex biomarker, integrating gene expression measurements and clinical parameters. Following the initial discovery, Biogazelle can support the further development of the biomarker into a clinical-grade test, offering in this way an end-to-end solution from RNA biomarker discovery to the development of a research-use-only (RUO) or clinical trial biomarker assay.

Learn More

Antisense Oligonucleotide Screening

To support the development of RNA-based therapeutics, we have put in place a comprehensive and high-throughput platform that can screen hundreds of antisense oligonucleotides (ASOs) for on-target knock-down efficiency. Consisting of a panel of 20 model cell lines that have high free-uptake capacity, our platform covers the majority of the human transcriptome. Our services include:


  • in vitro ASO efficacy screening
  • ASO specificity analysis
  • understanding drug mode of action
  • development of a companion diagnostic test

Learn More

Explore drug MOA with high-throughput expression profiling

To support early drug discovery we have developed a proprietary low-cost, high-throughput molecular cellular phenotyping service. HTPathwaySeq allows you to characterize therapeutic molecules, including small molecules and RNA targeting agents such as siRNAs and antisense oligonucleotides. By measuring the activity of molecular pathways through such an expression profiling approach, we provide insights into drug mode of action as well as potential safety issues, compound similarities and target deconvolution. An example application in the case of RNA therapeutic molecules is the study of off-target effects, which can yield novel insights in disease pathways and potentially novel therapeutic targets.

Learn More

Go to article: Home | Under the microscopeGo to article: In this issueGo to article: SHL Medical Company InsightGo to article: SHL MedicalGo to article: ContentsGo to article: MimotopesGo to article: NewsGo to article: VEGA AustraliaGo to article: Covid-19 executive briefing by GlobalDataGo to article: WipotecGo to article: Nasal spray vaccine for Covid-19Go to article: Datwyler Company Insight Go to article: DatwylerGo to article: Covid-19 clinical trials continue to rise in BrazilGo to article: BiogazelleGo to article: AstraZeneca’s Phase I / II Covid-19 vaccine trial Go to article: SwiftpakGo to article: MTPA resumes screening and enrolment for global Phase III clinical trial of MT-1Go to article: Biesterfeld Go to article: The pharma industry briefingGo to article: From antitoxins to Covid-19 drugs: charting the history of antibody drugsGo to article: Quality control: pharma manufacturing inspections explainedGo to article: Molnár-Institute Company InsightGo to article: Molnar-InstituteGo to article: Oxytocin: the therapeutic potential of the ‘love hormone’Go to article: AI-enabled risk detection in pharma manufacturingGo to article: Dr. Paul LohmannGo to article: Addressing the long-term effects of Covid-19Go to article: Eyes on the prize: the latest in retinitis pigmentosa gene therapiesGo to article: HOF Sonderanlagenbau Company Insight Go to article: HOF SonderanlagenbauGo to article: Breaking the taboo: disrupting the fertility sectorGo to article: Neutralising the gluten threat: are we on the cusp of a coeliac disease breakthrough? Go to article: Nolato Company Insight Go to article: NolatoGo to article: Pharmacovigilance case intake: why the hesitation to automate?Go to article: Deals in brief powered by GlobalDataGo to article: The key list powered by GlobalDataGo to article: Zenatek Go to article: Global markets and indices powered by GlobalDataGo to article: Macro-economic indicators (1 of 2) powered by GlobalDataGo to article: Macro-economic indicators (2 of 2) powered by GlobalDataGo to article: EventsGo to article: Next issue